News Releases

July 5, 2024	LakeShore Biopharma to Hold an Extraordinary General Meeting on July 25, 2024, Pursuant to Shareholders' Requisition
May 24, 2024	YS Biopharma Announces Name Change to LakeShore Biopharma
May 21, 2024	YS Biopharma Announces Results of Extraordinary General Meeting
May 7, 2024	YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer
April 29, 2024	YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
April 19, 2024	YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024
April 18, 2024	YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine
April 16, 2024	YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024
April 9, 2024	YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine
April 3, 2024	YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility

Print Page

Email Alerts

RSS Feeds

Contact IR

Site Map Terms of Use Privacy

Contact Info

LakeShore Biopharma, Ltd.

11 Firstfield Road Suite A
Gaithersburg, Maryland 20878 USA

Tel: +86 (10) 61253627

ir@lakeshorebio.com